This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
CARsgen Therapeutics has announced a col labor ation with Huadong Medicine to commercialise zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. Under the collaboration, Huadong Medicine will have the exclusive right to commercialise CARsgen’s CT053 in mainland China. By Cytiva Thematic.
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy.
Digital medicine is emerging as a revolutionary field that can transform the entire spectrum of healthcare, from proactive prevention to effective treatment of diverse medical conditions. Download POV Marketers must position the brand at the intersection of clinical and economic benefits and technology.
Four major trends came to light from CIRS’ most recent analysis of new active substance (NAS) approvals for the European Medicines Agency (EMA), US Food and Drug Administration (FDA), Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Swissmedic and the Australian Therapeutic Goods Administration (TGA).
GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. GenScript ProBio CEO Dr Brian Min said: “We are delighted to enter into this strategic partnership with RVAC Medicines.
And delays in the supply chain, even for short periods of time can potentially affect the efficacy of medicines, lead to longer-term supply bottlenecks, and ultimately prevent people from getting access to the critical medicines they need. Download to learn more. Please check your email to download the Whitepaper.
The most likely reason to visit a pharma website for HCPs is to download the product label. Pharma websites are a resource, but they don’t provide what they need and want to prescribe the drug. The feedback suggests that pharma has significant opportunities to get closer to HCPs via more transparency about drug trials and data.
Establish a small steering committee to co-create online course content related to updates in embryology and fertility medicine. To learn more about our client’s approach and the outcomes of this project, download the full customer story below. ? Download PDF. Download: Customer Success Story.
RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. RVAC Medicines CEO Dr Sean Fu said: “We are excited to begin this collaboration with Dr Weissman, a pioneer in the field of mRNA vaccines and therapeutics.
1 The European Directorate for the Quality of Medicines & Healthcare (EDQM) also accepted LBP as a new category of medicinal products for the European market in 2019. Download and read more now… .
Oral liquid medicine manufacturer Rosemont Pharmaceuticals has announced the acquisition of Lucis Pharma. Rosemont believes this acquisition will allow it to enter the single-use sachet pharmaceutical market, expanding its liquid medicines portfolio in a growing market. Evaluate the effects of COVID-19 on the sector.
DOWNLOAD THE FULL ARTICLE HERE. The post Battling breast cancer with precision medicine appeared first on. Without my family guiding me and helping me to find multiple opinions and navigate the healthcare system, I would not be alive today.
Under the deal, Prevail obtains exclusive rights to use Scribe’s CRISPR X-Editing (XE) technologies to develop the medicines. The deal will see the integration of Scribe’s new CRISPR by Design approach and Prevail’s expertise in developing genetic medicines for neurological disorders for specific genetic targets.
Moderna has announced that its cancer vaccine mRNA-4157/V940 along with Keytruda secured the European Medicines Agency (EMA) Priority Medicines (PRIME) scheme designation for the adjuvant treatment of high-risk stage III/IV melanoma patients after complete resection.
These groundbreaking discoveries ushered in a new age of precision and personalized medicine, leading to innovations in novel targeted proteins, cell and gene therapies, and medical devices, which are often accompanied by bespoke diagnostic and testing criteria. DOWNLOAD THE FULL ARTICLE HERE.
Vertex Pharmaceuticals chief medical officer and Global Medicines Development and Medical Affairs executive vice-president Carmen Bozic said: “The completion of our exa-cel global regulatory filings is a historic milestone. “We
Meeting strict client timelines is essential for clinical trials, but complications can arise when dealing with investigational medicinal products (IMPs) across several countries. Depending on the type of product and its purpose, secondary packaging materials ensure the stability and integrity of the investigational medicinal product.
Chinese biotech company LaNova Medicines and AstraZeneca have entered an exclusive licence deal for La Nova’s LM-305. LaNova Medicines founder, chair and CEO Dr Crystal Qin stated: “LaNova Medicines has a strong focus on discovering and developing innovative medicines in the ADC and immuno-oncology fields.
Abacus Medicine Pharma Services (AMPS) and AddMedica are proud to announce the signing of a partnership agreement for the marketing and distribution of Siklos® in Benelux. 100mg (3422086) Abacus Medicine Pharma Services is part of the Abacus Medicine Group, a fast-growing supplier of original prescription medicines.
Cell One Partners has announced a strategic collaboration with the Center for Breakthrough Medicines (CBM) to expedite the development and commercialisation of cell and gene therapies. Cell One Partners offers virtual company creation and management to its clients for complete aspects of the development and commercialisation of drugs.
With cell and gene therapy, not only does it offer the management of symptoms like other conventional medicines, but it also offers the potential of a cure. RoslinCT began as a spin-out from the Roslin Institute – now part of the University of Edinburgh – in 2006, providing expertise in regenerative medicine. Download to learn more.
Personalised medicines will also be developed at the centre. This facility will join the NHSBT’s five other sites throughout the UK, which provide a combination of stem cell and immunotherapy support services, GMP cell therapy manufacturing services, and advanced therapy medicinal products (ATMP) storage and distribution.
Moderna CEO Stéphane Bancel said: “Since our inception, we have always strived to be at the forefront of cutting-edge technology, leveraging innovations to deliver the greatest possible impact to people through mRNA medicines. “We Moderna aims to leverage MoLFormer to optimise lipid nanoparticles and mRNA.
Brazilian public spending on healthcare, drug pricing reforms and remote medicine. If this act goes through, it will increase access to medicines and treatments, and significantly expand the available market, especially for those in rural areas previously unable to access services such as diagnostics. Free Whitepaper. United Kingdom.
Abacus Medicine Pharma Services (AMPS) and Laboratoires CTRS, marketing authorization holder of Orphacol®, are proud to announce a strategic partnership that ensures continuous stock of Orphacol® in Spain. Our ambition is to provide better access to medicines and better healthcare to patients around the world.
Download EPR ’s Issue 3 2023 to read AC Immune’s article on vaccine development : Paving the way for anti-Abeta active immunotherapy European Pharmaceutical Review Issue 3 2023 The post Alzheimer’s vaccine granted Fast Track designation appeared first on European Pharmaceutical Review.
The knowledge that is gained will boost Roche’s drug discovery and development projects and enable medicines to reach patients faster. They have the potential to enhance almost all the steps involved in the research and development of innovative medicine. Please check your email to download the Whitepaper.
Its focus areas include human systems, precision diagnostics, data sciences, next-generation biomanufacturing, and genomic medicines. The programme aims to develop advanced technologies and applications to improve human health. The University of Pennsylvania Immunotherapy Richard W.
Xilis CEO and co-founder Dr Xiling Shen said: “Our research suggests the MOS platform has the potential to offer new capabilities and to improve the efficiency of developing innovative drugs and cell therapies over current xenograft and organoid models, which we hope will bring medicines to patients more quickly. “We
The Indian Council of Medical Research (ICMR) has entered a memorandum of agreement (MoA) with the Ministry of Ayush to carry out research in the field of integrated medicine. Please check your email to download the Whitepaper.
Under the multi-year strategic partnership, Prevail will detect and advance capsids, which are clinically translatable, along with its cargo to develop the transformative genetic medicines by using Capsida’s novel adeno-associated virus (AAV) engineering platform. By Cytiva Thematic.
I downloaded TikTok and Instagram and started making ridiculous videos about living life with a disability, about being a young face of ALS, about the disgusting taste of my medicine — anything I could do to get people googling ALS and learning more.” Download the free guide 1. I did what any millennial would do.
ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients. Under the agreement, Asieris will use the advanced RNA modulation technologies, BindeR and SpliceR, of ReviR for identifying and developing new therapies that target RNA for cancer treatment.
Orkambi is an oral medicine that uses a fixed combination dose of lumacaftor and ivacaftor. The FDA initially granted Orkambi approval in 2015 as the first medicine to treat the underlying cause of CF for individuals aged 12 or older with two copies of the F508del mutation. Please check your email to download the Report.
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. Dr. Jerry Mendell, MD, professor of paediatrics and neurology at the Ohio State University College of Medicine, is optimistic for its approval and says the drug has a good safety profile. Please check your email to download the Report.
In recent years, nitrosamines have been detected in various medicines, leading to voluntary product recalls from the market. Nitrosamines analysis is, thus, key to ensuring safety and quality in the pharmaceutical industry. This is achieved through a combination of risk assessment and analytical testing.
After a physician orders a product, DTx Connect delivers a welcome message to the patient via text or within a patient portal, along with an electronic link to download the DTx and any accompanying educational materials. billion in 2021.
By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
Download the full event guide here for the official agenda. Kate Fitzgerald , Professor & Vice Chair, Department of Medicine, Division of Innate Immunity, University of Massachusetts Chan Medical School. Download your event guide to see what these experts will be discussing. Alan Watt , Chief Scientific Officer, NodThera.
ElevateBio intends to use the funds to advance its genetic medicine current good manufacturing practice (cGMP) and process development business, BaseCamp. The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform.
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz. Tune in to learn more about the world of off-patent medicines: an important category of medications that isn’t going away.
The BGTC is part of the accelerating medicines partnership (AMP) programme and is managed by the Foundation for the National Institutes of Health (FNIH). Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content